🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to scientists.

An International Challenge

Cases of gonorrhoea are increasing worldwide, with estimates suggesting in excess of 82 million infections per year. Notably increased rates are observed in Africa and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the reality of rising global incidence, the spread of superbugs and the extremely scarce treatment choices at this time.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Secure Authorization

One new antibiotic, marketed under the name a brand name, was approved by the US Food and Drug Administration in recent days for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in concurrent days. This drug, which is also used to treat UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This milestone marks a major breakthrough in the treatment of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Results and Worldwide Availability

Based on findings published in a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which uses an injection and a pill. The study involved hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the authority to register and commercialise the drug in many regions with limited resources.

Clinicians treating patients have voiced optimism. The availability of a easy-to-administer therapy like this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as vital to alleviate the strain of the disease for individuals and to halt the transmission of untreatable gonorrhoea worldwide.